Catalpol activated the PI3K/Akt/mTOR pathway, decreasing the expression of miR-124 and increasing the expression of downstream protein S6, thus enhancing in vivo axon growth and neuronal survival in stroke models. This evidence concerns the gene AKT1 and stroke disorder.